Interleukin-15 antagonist peptide
US7736638B2 · kind B2 · utility
4Cited by
3References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 16, 2005 |
| Grant date | Jun 15, 2010 |
| Priority date | — |
| Expiry date | Dec 13, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K39/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor a subunit (IL15Rα) and TNFα-mediated apoptosis.Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15Rα expression is associated to the disease progression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.